William Blair initiated research coverage of Intellia Therapeutics, Inc. (NTLA $95.86), a clinical-stage genome-editing company focused on using CRISPR-Cas9 technology to create in vivo and ex vivo therapies for diseases with high unmet need.
Analyst Raj Prasad expects several updates from the company in 2022, including data from the Phase I study of lead candidate NTLA-2001 in ATTR (transthyretin amyloidosis) patients with polyneuropathy (ATTRv-PN); completion of enrollment in the NTLA-2001 Phase I study in ATTRv-PN and ATTR patients with cardiomyopathy (ATTR-CM, a large TAM expansion) arms; interim data from its Phase I/II trial with NTLA-2002 in hereditary angioedema; two new in vivo development candidates; enrollment of patients in a Phase I/IIa study of its lead ex vivo program, NTLA-5001, in acute myeloid leukemia; and the nomination of a wholly owned allogeneic ex vivo candidate.
“Intellia has established itself as a pioneer in the in vivo application of CRISPR-Cas9 editing,” Dr. Prasad said, “and has leveraged its platform technology in combination with additional proprietary capabilities, such as nonviral delivery, to address unmet need across genetic diseases, immuno-oncology, and autoimmune indications. The company has two partnerships with large biotechnology companies: an in vivo partnership with Regeneron that includes up to 15 targets with a mix of co-developed and licensed programs and an ex vivo partnership with Novartis that is focused primarily on a sickle cell disease program called OTQ923, along with other CAR-T, hematopoietic stem cell, and ocular stem cell indications that are yet to be disclosed.”
Dr. Prasad continued, “For NTLA-2001, we see a $1 billion-plus market opportunity in the ATTR-PN population that expands to a multibillion opportunity if successful in the larger ATTR-CM population. We assume a 2026 U.S. launch for NTLA-2001 in the ATTR-PN subpopulation and a 2027 launch in the ATTR-CM population. While we expect proof-of-concept clinical data from NTLA-2002 in the second half of the year, we believe the asset is de-risked from the Phase I NTLA-2001 data because of similarities in product composition. From the earlier-stage pipeline, both NTLA-5001 in AML and NTLA-3001 in A1ATD are using approaches that would expand the platform potential of Intellia’s CRISPR-Cas9 technology.”
William Blair is the premier global boutique with expertise in investment banking, investment management, and private wealth management. We provide advisory services, strategies, and solutions to meet our clients’ evolving needs. As an independent and employee-owned firm, together with our strategic partners, we operate in more than 20 offices worldwide.*
*Includes strategic partnerships with Allier Capital, BDA Partners, and Poalim Capital Markets.
William Blair or an affiliate does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. This report is not intended to provide personal investment advice. The opinions and recommendations herein do not take into account individual client circumstances, objectives, or needs and are not intended as recommendations of particular securities, financial instruments, or strategies to particular clients. The recipient of this report must make its own independent decisions regarding any securities or financial instruments mentioned herein.
William Blair or an affiliate is a market maker in the security of Intellia Therapeutics, Inc.
William Blair or an affiliate expects to receive or intends to seek compensation for investment banking services from Intellia Therapeutics, Inc. or an affiliate within the next three months.
Officers and employees of William Blair or its affiliates (other than research analysts) may have a financial interest in securities of Intellia Therapeutics, Inc.
Please contact us at +1 800 621 0687 or view disclosures on our coverage list.
Additional information is available upon request.
Current Ratings Distribution (as of 2/17/22)
Outperform (Buy): 77%
Market Perform (Hold): 23%
Underperform (Sell): 1%
Inv. Banking Relationships*
Outperform (Buy): 30%
Market Perform (Hold): 7%
Underperform (Sell): 0%
* Percentage of companies in each rating category that are investment banking clients, defined as companies for which William Blair has received compensation for investment banking services within the past 12 months.
The compensation of the research analyst is based on a variety of factors, including the quality and accuracy of research, client feedback, contributions to other firm departments, competitive factors, and firm profitability.
OTHER IMPORTANT DISCLOSURES
Stock ratings and valuation methodologies: William Blair & Company, L.L.C. uses a three-point system to rate stocks. Individual ratings reflect the expected performance of the stock relative to the broader market (generally the S&P 500, unless otherwise indicated) over the next 12 months. The assessment of expected performance is a function of near-, intermediate-, and long-term company fundamentals, industry outlook, confidence in earnings estimates, valuation (and our valuation methodology), and other factors. Outperform (O) – stock expected to outperform the broader market over the next 12 months; Market Perform (M) – stock expected to perform approximately in line with the broader market over the next 12 months; Underperform (U) – stock expected to underperform the broader market over the next 12 months; not rated (NR) – the stock is not currently rated. The valuation methodologies include (but are not limited to) price-to-earnings multiple (P/E), relative P/E (compared with the relevant market), P/E-to-growth-rate (PEG) ratio, market capitalization/revenue multiple, enterprise value/EBITDA ratio, discounted cash flow, and others. Stock ratings and valuation methodologies should not be used or relied upon as investment advice. Past performance is not necessarily a guide to future performance.
The ratings and valuation methodologies reflect the opinion of the individual analyst and are subject to change at any time.
Our salespeople, traders, and other professionals may provide oral or written market commentary, short-term trade ideas, or trading strategies—to our clients, prospective clients, and our trading desks—that are contrary to opinions expressed in this research report. Certain outstanding research reports may contain discussions or investment opinions relating to securities, financial instruments and/or issuers that are no longer current. Always refer to the most recent report on a company or issuer. Our asset management and trading desks may make investment decisions that are inconsistent with recommendations or views expressed in this report. We will from time to time have long or short positions in, act as principal in, and buy or sell the securities referred to in this report. Our research is disseminated primarily electronically, and in some instances in printed form. Research is simultaneously available to all clients. This research report is for our clients only. No part of this material may be copied or duplicated in any form by any means or redistributed without the prior written consent of William Blair & Company, L.L.C.
This is not in any sense an offer or solicitation for the purchase or sale of a security or financial instrument. The factual statements herein have been take from sources we believe to be reliable, but such statements are made without any representation as to accuracy or completeness or otherwise, except with respect to any disclosures relative to William Blair or its research analysts. Opinions expressed are our own unless otherwise stated and are subject to change without notice. Prices shown are approximate.
This material is distributed in the United Kingdom and the European Economic Area (EEA) by William Blair International, Ltd., authorized and regulated by the Financial Conduct Authority (FCA). William Blair International, Limited is a limited liability company registered in England and Wales with company number 03619027. This material is only directed and issued to persons regarded as Professional investors or equivalent in their home jurisdiction, or persons falling within articles 19 (5), 38, 47, and 49 of the Financial Services and Markets Act of 2000 (Financial Promotion) Order 2005 (all such persons being referred to as “relevant persons”). This document must not be acted on or relied on by persons who are not “relevant persons.”
“William Blair” and “R*Docs” are registered trademarks of William Blair & Company, L.L.C. Copyright 2022, William Blair & Company, L.L.C. All rights reserved.